• 1
    Alexanian, R., Bonnet, J., Gehan, E., Haut, A., Hewlett, J., Lane, M., Monto, R., Wilson, H. (1972) Combination chemotherapy for multiple myeloma. Cancer, 30, 382 389.
  • 2
    Anderson, K.C., Andersen, J., Soiffer, R., Freedman, A.S., Rabinowe, S.N., Robertson, M.J., Spector, N., Blake, K., Murray, C., Freeman, A., Coral, F., Marcus, K.C., Mauch, P., Nadler, N.M., Ritz, J. (1993) Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood, 82, 2568 2576.
  • 3
    Attal, M., Harousseau, J.L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.P.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., Bataille, R., for the Intergroup Francais du Myelome (1996) A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91 97.
  • 4
    Baldini, L., Radaelli, F., Chiorboli, O., Fumagalli, S., Cro, L., Segala, M., Cesana, B.M., Polli, E.E., Maiolo, A.T. (1991) No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide and prednisone. Cancer, 68, 62 67.
  • 5
    Ballester, O.F., Moscinski, L.C., Fields, K.K., Hiemenz, J.W., Zorsky, P.E., Goldstein, S.C., Saba, H.I., Spiers, A.S.D., Kronisj, L., Sullivan, P., Elfenbein, G.J. (1997) Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. British Journal of Haematology, 96, 746 748.
  • 6
    Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789 793.
  • 7
    Belch, A., Shelley, W., Bergsagel, D., Wilson, K., Klimo, P., White, D., Willan, Q. (1988) A randomised trial of maintenance versus no maintenance melphalan and prednisone therapy in responding multiple myeloma patients. British Journal of Cancer, 57, 94 99.
  • 8
    Bergsagel, D.E. (1975) Plasma cell myeloma: prognostic factors and criteria of response to therapy. Cancer Therapy: Prognostic Factors and Criteria of Response (ed. by M. J. Staquet), pp. 73 87. Raven Press, New York.
  • 9
    Bergsagel, D.E. (1998) Chemotherapy of myeloma. Multiple Myeloma: Biology and Management (ed. by J. S. Malpas, D. E. Bergsagel, R. A. Kyle and K. C. Anderson), pp. 269 302. Oxford University Press.
  • 10
    Bergsagel, D.E., Bailey, A.J., Langley, G.R., Macdonald, R.N., White, D.F., Millar, A.B. (1979) The chemotherapy of myeloma and the incidence of plasma cell leukemia. New England Journal of Medicine, 301, 743 748.
  • 11
    Bird, J.M., Russell, N.H., Samson, D. (1993) Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence of cure in long-term survivors. Bone Marrow Transplantation, 12, 651 654.
  • 12
    Bjorkstrand, B., Ljungman, P., Bird, J.M., Samson, D., Brandt, L., Alegre, A., Auzanneau, G., Blade, J., Brunet, S., Carlson, K., Cavo, M., Ferrant, A., Gravett, P., de Laurenzi, A., Prentice, H.G., Proctor, S., Remes, K., Troussard, X., Verdonck, L.F., Williams, C., Gahrton, G. (1995a) Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells, Daytona, 13, (Suppl. 2), 140 146.
  • 13
    Bjorkstrand, B., Ljungman, P., Bird, J.M., Samson, D., Gahrton, G. (1995b) Double high-dose therapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplantation, 15, 367 371.
  • 14
    Blade, J., Lopez-Guillermo, A., Bosch, F., Cervantes, F., Montserrat, E., Rozman, C. (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 88, 117 121.
  • 15
    Blade, J., Rozman, C., Montserrat, E., Cervantes, F., Feliu, E., Granena, A., Marin, P., Nomdedeu, B. (1986) Treatment of alkylating agent resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). European Journal of Cancer and Clinical Oncology, 22, 1193 1197.
  • Chronic Leukemia and Myeloma Task Force of the National Cancer Institute (
    1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemotherapy Reports, 4, 145 158.
  • 17
    Chronic Leukemia and Myeloma Task Force (1968) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemotherapy Reports, 1, 17.
  • 18
    Cross, N.C.P., Lin, F., Chase, A., Bungey, J., Hughes, T.P., Goldman, J.M. (1993) Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia after bone marrow transplantation. Blood, 82, 1929 1936.
  • 19
    Dimopoulos, M.A., Alexanian, R., Przepiorka, D., Hester, J., Andersson, B., Giralt, S., Mehta, R., van Biesen, K., Delasalle, K.B., Reading, C., Deisseroth, A.B., Champlin, R.E. (1993) Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood, 82, 2324 2328.
  • 20
    Durie, B.G.M., Russell, D.H., Salmon, S.E. (1980) Reappraisal of plateau phase in myeloma. Lancet, ii, 65 68.
  • 21
    Gahrton, G., Tura, S., Ljungman, P., Belanger, B., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., Lowenberg, B., Nikoskelainen, J., Reiffers, J., Samson, D., Verdonck, L., Volin, L. (1991) Allogeneic bone marrow transplantation in multiple myeloma using HLA-matched sibling donors. New England Journal of Medicine, 325, 1267 1272.
  • 22
    Gahrton, G., Tura, S., Ljungman, P., Blade, J., Brandt, L., Cavo, M., Facon, T., Gratwohl, A., Hagenbeek, A., Jacobs, P., de Laurenzi, A., Van Lint, M., Michallet, M., Nikoskelainen, J., Reiffers, J., Samson, D., Verdonck, L.F., de Witte, T., Volin, L. (1995) Prognostic factors in allogeneic transplantation in multiple myeloma. Journal of Clinical Oncology, 13, 1312 1322.
  • 23
    Gore, M.E., Selby, P.J., Viner, C., Clark, P.I., Meldrum, M., Millar, B., Bell, J., Maitland, J.A., Milan, S., Judson, I.R., Zuiable, A., Tillyer, C., Slevin, M., Malpas, J.S., McElwain, T.J. (1989) Intensive treatment of multiple myeloma and criteria for complete remission. Lancet, ii, 879 881.
  • 24
    Holland, J.F., Hosley, H., Scharlau, C., Carbone, P.P., Frei, E., Brindley, C.O., Hall, T.C., Shmider, B.I., Gold, G.L., Lasagna, L., Owens, A.H., Miller, S.P. (1966) A controlled trial of urethane treatment in multiple myeloma. Blood, 27, 328 342.
  • 25
    Joshua, D.E., Penny, R., Matthews, J.P., Laidlaw, C.R., Gibson, J., Bradstock, K., Wolf, M., Goldstein, D. (1997) Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. British Journal of Haematology, 97, 38 45.
  • 26
    Joshua, D.E., Snowdon, L., Gibson, H., Iland, H., Brown, R., Warburton, P., Kulkarni, A., Vincent, P., Young, G., Gatenby, P., Bassten, A., Kronenburg, H. (1991) Multiple myeloma: plateau phase revisited. Hematology Reviews, 5, 59 66.
  • 27
    Korst, D.R., Clifford, G.O., Fowler, W.M., Louis, J., Will, J., Wilson, H.E. (1964) Multiple myeloma. II. Analysis of cyclophosphamide therapy In 165 patients. Journal of the American Medical Association, 189, 156 161.
  • 28
    Kyle, R.A. & Greipp, P.R. (1980) Smoldering multiple myeloma. New England Journal of Medicine, 302, 1347 1349.
  • 29
    MacLennan, I.C.M., Chapman, C., Dunn, J., Kelly, K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 339, 200 205.
  • 30
    MacLennan, I.C.M., Drayson, M., Dunn, J. (1994) Multiple myeloma. British Medical Journal, 308, 1033 1036.
  • 31
    Malpas, J.S. (1998) Clinical presentation and diagnosis. Myeloma: Biology and Management (ed. by J. S. Malpas, D. E. Bergsagel, R. A. Kyle and K. C. Anderson), pp. 187 209. Oxford University Press.
  • 32
    Marmont, F., Levis, A., Falda, M., Resegotti, L. (1991) Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. Annals of Oncology, 2, 191 195.
  • 33
    McLaughlin, P. & Alexanian, R. (1982) Myeloma protein kinetics following chemotherapy. Blood, 60, 851 855.
  • 34
    Oivanen, T.M., for the Finnish Leukaemia Group (1996) Plateau phase in myeloma: an analysis of long-term follow-up of 432 patients. British Journal of Haematology, 92, 834 839.
  • 35
    Palmer, M., Belch, A., Hanson, J., Brox, L. (1989) Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. British Journal of Cancer, 59, 110 112.
  • 36
    Samson, D., Gaminara, E., Newland, A., van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M., Barrett, A.J., Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882 885.
  • 37
    Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Lee, M., Wu, C.H., Cao, J., Lee, J.C., Lichtenstein, A., Lill, M., Berenson, R., Berenson, J. (1998) Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplantation, 21, 141 145.
  • 38
    Selby, P.J., MacElwain, T.J., Nandi, A.C., Perren, J.J., Powles, R.L., Tillyer, C.R., Osborne, R.J., Slevin, M.L., Malpas, J.S. (1987) Multiple myeloma treated with high-dose intravenous melphalan. British Journal of Haematology, 66, 55 62.
  • 39
    Vesole, D.H., Tricot, G., Jagannath, S., Desikan, K.R., Siegel, D., Bracy, D., Miller, L., Cheson, B., Crowley, J., Barlogie, B. (1996) Autotransplants in myeloma: what have we learned? Blood, 88, 838 847.